Diverse enrollment is not only a campaign problem. Study design, site selection, eligibility criteria, visit burden, language access, and follow-up operations shape who can realistically participate.
In this guide
Key points
- Diversity planning should begin before recruitment opens, not after enrollment falls behind.
- Sponsors and sites should review protocol burden, site access, language support, transportation, childcare, and screen-failure patterns together.
- TrialsNest can support the operating rhythm by keeping source quality, screen failures, follow-up status, and blockers visible without replacing authorized study-team decisions.
The campaign is usually too late
Many teams try to solve representation gaps after a study is already open by adding more ads, more referrals, or more community outreach. Those tactics can help, but they cannot fully repair a protocol, site map, or visit schedule that made participation difficult from the start.
The FDA's June 2024 draft guidance on Diversity Action Plans describes expectations around the form, content, timing, and waiver process for certain clinical studies. Even when a specific plan is not required, the operational lesson is clear: representative enrollment needs to be designed, measured, and managed.
Review the study before reviewing the media plan
Start with the parts of the study that create access barriers: inclusion and exclusion criteria, number of visits, visit timing, required procedures, reimbursement, travel distance, language support, and whether local or hybrid activities are possible.
The National Academies' review of underrepresentation in clinical research describes barriers across the study lifecycle, including site selection, recruitment methods, eligibility criteria, consent processes, remuneration, and multilingual materials. It also names practical barriers such as transportation and childcare.
That review should happen while protocol operations, site mix, patient materials, and referral expectations can still change. Once recruitment opens, teams often have fewer options and more pressure to solve structural issues with media spend.
Use a case-study lens
Consider a sponsor that opens a study at three high-performing academic sites, then notices low enrollment among rural and lower-income patients. A late advertising push may raise awareness, but it does not solve travel distance, missed-work risk, language access, or site availability.
A stronger upstream plan would compare target population geography against site access, budget for participant support where appropriate, prepare multilingual patient-facing materials, and define which screen-failure reasons must trigger review.
The plan should also name who owns each barrier. Some fixes belong to sponsor protocol review, some to site staffing or scheduling, and some to patient-facing education. Without ownership, diversity planning becomes a slide instead of an operating rhythm.
Track the blockers while there is still time to act
A practical diversity plan needs recurring operational review. Sponsors and sites should compare inquiry sources, prescreen completion, screen-failure reasons, no-response patterns, travel barriers, records blockers, and scheduled-visit conversion by site.
TrialsNest can help teams keep those signals organized as part of daily recruitment workflow. The goal is not to automate final eligibility. The goal is to make avoidable access barriers visible early enough for the right team to adjust.
Useful review questions include whether the same groups are repeatedly dropping before prescreen completion, whether certain sites have avoidable scheduling barriers, and whether screen failures point back to criteria that were not pressure-tested before launch.
Sources used for this guide
FDA Diversity Action Plans draft guidance explains expected timing and content for certain study diversity plans: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies
The National Academies review describes lifecycle barriers to representation, including site selection, eligibility criteria, consent, language access, transportation, and childcare: https://www.ncbi.nlm.nih.gov/books/NBK584407/
Sources and editorial notes
Published .
This guide explains recruitment work and questions to discuss with your team.
This information is educational. Your study team makes medical, eligibility, and enrollment decisions.
See TrialsNest in action
Bring this workflow into one place.
Manage inquiries, follow-ups, records, and visits. Keep sponsors updated on progress.
Sponsor portfolio
39 / 50 enrolled78%
74 / 120 enrolled62%
9 / 10 enrolled90%
Keep reading
Diversity action plan weekly recruitment review template for sponsors
A weekly review template for translating diversity action planning into recruitment source review, site follow-up, access barriers, and sponsor decisions.
How to use real-world data without overpromising in trial planning
A practical guide for sponsors using real-world data to improve clinical trial feasibility, recruitment planning, and protocol design without creating false confidence.
Clinical trial recruitment software resources
Resources for teams comparing clinical trial recruitment software, patient recruitment software, dashboards, workflow coverage, implementation plans, and ROI.
Clinical trial recruitment software for CRO clinical operations teams
CRO teams need recruitment software that explains where study execution is slowing down across sites, sources, records, follow-up, scheduling, and sponsor updates. The best system supports oversight without taking ownership away from site teams.
